Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26683139 | 0.78 | TDP1 (0.40) | TDP1 | |
| SCHEMBL26683281 | 0.67 | BPTF (0.44) | — | |
| SCHEMBL20042488 | 0.65 | DAO (0.36) | — | |
| SCHEMBL5849832 | 0.61 | EGFR (0.33) | — | |
| SCHEMBL8113716 | 0.60 | SMN1; SMN2 (0.47) | — | |
| SCHEMBL26973212 | 0.60 | TDP1 (0.30) | TDP1 | |
| SCHEMBL23705847 | 0.58 | TDP1 (0.32) | TDP1 | |
| SCHEMBL2781561 | 0.56 | KDM4E (0.50) | TDP1 | |
| SCHEMBL9877772 | 0.56 | TRPA1 (0.31) | — | |
| SCHEMBL30973442 | 0.55 | TDP1 (0.30) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4522277-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220137-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304596-A1 | PYRAZINE DERIVATIVES AND USES THEREOF | VHL, BRCA1, SF3B5 | TDP1 1797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.